Related Experiment Video
Updated: Jun 23, 2025

Protocol to Create Chronic Wounds in Diabetic Mice
Published on: September 25, 2019
Unveiling the Detrimental Effect of Glipizide on Structure and Function of Catalase: Spectroscopic, Thermodynamics
Mohd Shahnawaz Khan1, Nojood Al-Twaijry2, Fai N Alotaibi2
1Department of Biochemistry, College of Science, King Saud University, 11451, Riyadh, Saudi Arabia. moskhan@ksu.edu.sa.
Abstract:
Free radicals, products of oxidative processes, induce cellular damage linked to diseases like Parkinson's and diabetes due to increased reactive oxygen species (ROS) levels. Catalase, crucial for scavenging ROS, emerges as a therapeutic agent against ailments including atherosclerosis and tumor progression. Its primary function involves breaking down hydrogen peroxide into water and oxygen. Research on catalase-drug interactions reveals structural changes under specific conditions, affecting its activity and cellular antioxidant balance, highlighting its pivotal role in defending against oxidative stress-related diseases. Hence, targeting catalase is considered an effective strategy for controlling ROS-induced cellular damage. This study investigates the interaction between bovine liver catalase and glipizide using spectroscopic and computational methods. It also explores glipizide's effect on catalase activity. More than 20% inhibition of catalase enzymatic activity was recorded in the presence of 50 µM glipizide. To investigate the inhibition of catalase activity by glipizide, we performed a series of binding studies. Glipizide was found to form a complex with catalase with moderate affinity and binding constant in the range of 3.822 to 5.063 × 104 M-1. The binding was spontaneous and entropically favourable. The α-helical content of catalase increased from 24.04 to 29.53% upon glipizide complexation. Glipizide binding does not alter the local environment surrounding the tyrosine residues while a notable decrease in polarity around the tryptophan residues of catalase was recorded. Glipizide interacted with numerous active site residues of catalase including His361, Tyr357, Ala332, Asn147, Arg71, and Thr360. Molecular simulations revealed that the catalase-glipizide complex remained relatively stable in an aqueous environment. The binding of glipizide had a negligible effect on the secondary structure of catalase, and hydrogen bonds persisted consistently throughout the trajectory. These results could aid in the development of glipizide as a potent catalase inhibitor, potentially reducing the impact of reactive oxygen species (ROS) in the human body.
Insights
Glipizide inhibits catalase activity, an enzyme that neutralizes harmful reactive oxygen species (ROS). This interaction shows potential for developing glipizide as a therapeutic agent against oxidative stress-related diseases.
Area of Science:
- Biochemistry
- Molecular Biology
- Pharmacology
Background:
- Free radicals and reactive oxygen species (ROS) contribute to cellular damage in diseases like Parkinson's and diabetes.
- Catalase is a key enzyme in scavenging ROS, making it a therapeutic target for oxidative stress-related conditions.
- Understanding drug interactions with catalase is crucial for developing effective antioxidant strategies.
Purpose of the Study:
- To investigate the interaction between bovine liver catalase and glipizide.
- To evaluate the effect of glipizide on catalase enzymatic activity.
- To explore the binding mechanism and structural changes of catalase upon glipizide complexation.
Main Methods:
- Spectroscopic techniques (e.g., fluorescence, circular dichroism) were employed.
- Computational methods, including molecular simulations, were utilized.
- Enzymatic activity assays were performed to quantify catalase inhibition.
Main Results:
- Glipizide inhibited catalase activity by over 20% at 50 µM.
- Glipizide formed a complex with catalase with moderate affinity (binding constant 3.822–5.063 × 10⁴ M⁻¹).
- Binding induced a slight increase in catalase's α-helical content and altered polarity around tryptophan residues.
Conclusions:
- Glipizide acts as a moderate inhibitor of bovine liver catalase.
- The binding is spontaneous and entropically favorable, with glipizide interacting with active site residues.
- These findings suggest glipizide's potential as a catalase inhibitor for managing ROS-induced cellular damage.
Related Concept Videos
Dipeptidyl Peptidase 4 Inhibitors
Oral Hypoglycemic Agents: Biguanides and Glitazones
Phase II Reactions: Glutathione Conjugation and Mercapturic Acid Formation
Several distinctive characteristics distinguish glutathione conjugation from other phase II...
Oral Hypoglycemic Agents: α-Glucosidase Inhibitors
Acarbose and miglitol are...
Enzymes
Enzyme deficiencies can often translate into life-threatening diseases. For example, a genetic abnormality resulting in the deficiency of the enzyme G6PD...
Oral Hypoglycemic Agents: Glinides

